On Friday, Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD), gained 7.90% to $14.34.
Amicus Therapeutics, declared the pricing of an underwritten offering of 16,981,132 shares of its common stock at $13.25 per share. The gross proceeds from the offering to Amicus are predictable to be $225 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus. In addition, Amicus has granted the underwriters a 30-day option to purchase up to an additional 2,547,170 shares of its common stock. The offering is predictable to close on June 17, 2015, subject to customary closing conditions.
J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. Cowen and Company, LLC is acting as lead manager and Janney Montgomery Scott LLC is acting as co-manager for the offering.
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Shares of Bristol-Myers Squibb Company (NYSE:BMY), declined -0.87% to $65.28, during its last trading session.
PeptiDream Inc., a Tokyo-based biopharmaceutical company, declared recently the achievement of a milestone in one of the discovery programs in its alliance with US-based Bristol-Myers Squibb (BMY). The milestone is the decision by Bristol-Myers Squibb to designate a Partnership Compound as a candidate for exploratory clinical development, indicating that the compound has met certain pre-defined criteria and is now suitable for exploratory clinical development. The compound will now proceed to IND-enabling studies. Achievement of this milestone entitles PeptiDream to receive an unrevealed payment specified in the research partnership and license agreement between PeptiDream and Bristol-Myers Squibb initiated October 15, 2010 and extended on October 15, 2012.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
Finally, SandRidge Energy, Inc. (NYSE:SD), ended its last trade with -1.77% loss, and closed at $1.11.
SandRidge Energy, has closed its formerly declared private offering of $1.25 billion in aggregate principal amount of senior secured notes due 2020. The Notes were issued at par and bear interest at a rate of 8.75% per annum. The Notes are secured on a second-lien priority basis and guaranteed by each of the Company’s auxiliaries that guarantee the Company’s revolving credit facility. In addition, the Company’s formerly declared amended and restated first-lien revolving bank credit facility with an initial $500 million borrowing base became effective recently.
The Company used a portion of the net proceeds from the offering of the Notes to repay all borrowings under its existing revolving credit facility and will use the remainder for general corporate purposes.
SandRidge Energy, Inc., an oil and natural gas company, explores for and produces oil and natural gas properties primarily in the Mid-Continent region of the United States. The company operates through three segments: Exploration and Production, Drilling and Oil Field Services, and Midstream Services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
